In this poster, Oxford Gene Technology (OGT) highlights the increasing role of molecular methods, specifically next-generation sequencing (NGS), in detecting measurable residual disease (MRD) in conditions like acute myeloid leukemia (AML). While real-time qPCR (RQ-PCR) and digital droplet PCR (ddPCR) are highly sensitive, they have limitations in detecting multiple targets in a single assay. NGS overcomes this limitation by allowing the evaluation of many genes and variant types in a single ass